SLC16A3 and breast carcinoma: Recent evidence has shown that the overexpression of MCT4 in CAF can be inhibited by the anti-oxidant N-acetyl-cysteine (NAC) during breast cancers, suggesting that targets on ameliorating oxidative stress and regulating the MCT4 expression may control the pathological progress of such cancers [189].